Serum Cystatin C Level as a Potential Indicator of Hepatic Fibrosis in Patients with Chronic Hepatitis B
Serum Cystatin C and Hepatic Fibrosis
DOI:
https://doi.org/10.5281/zenodo.17456125Keywords:
cystatin C, hepatic fibrosis, chronic hepatitis BAbstract
Objective
The aim of this study is to investigate the usability of serum cystatin C levels as a non- invasive fibrosis marker in patients with chronic hepatitis B.
Materials and methodsThe study included 122 patients [63 chronic active hepatitis B (HBeAg+chronic hepatitis B), 29 chronic inactive hepatitis B (HBeAg-chronic HBV infection), and 30 patients on oral antiviral therapy (at least 6 months of treatment and HBVDNA negative)] and 30 healthy controls. According to the Modified Ishak Score, chronic active hepatitis B patients with a fibrosis score of 0–1 were classified as having "no fibrosis/mild fibrosis" and 2–6 as having "advanced (severe) fibrosis". Statistical analysis was used to determine the relationship between the groups.
ResultsA significant difference was found in terms of HBVDNA (p=0.007), and the histological activity index (p<0.001) between the no fibrosis/mild fibrosis and advanced fibrosis groups. HBVDNA (p<0.001), cystatin C level (p<0.001) were found to be significantly different between advanced fibrosis and oral antiviral treatment patient groups. HBVDNA (p=0.000), and cystatin C (p<0.001) levels were found to be significantly different among patients with chronic active hepatitis and receiving oral antiviral therapy. The difference between chronic active hepatitis and healthy control groups was significant in terms of cystatin C (p=0.010) levels.
ConclusionThe serum cystatin C level changes in parallel with the HBVDNA level suggests that it is a marker that can be used as an indicator of replication and therefore indirectly of hepatic fibrosis.
Downloads
References
1. MAJA T., LISE L.G., EMILIE K.D., ALEKSANDER K. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ open, 2013. 3(8): p. e003265.
2. NIRO G.A., IPPOLITO A.M., FONTANA R., VALVANO M.R., GIOFFREDA D., LACOBELLIS A., et al. Long‐term outcome of hepatitis B virus‐related Chronic Hepatitis under protracted nucleos (t) ide analogues. Journal of viral hepatitis, 2013. 20(7): p. 502-509.
3. FEHMI T., CIHAN Y., SABAHATTIN K., MESUT A., ESRA G.A., HIKMET A., et al. Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turk J Gastroenterol, 2017. 28(2): p. 73-83.
4. SHI G.P., SUKHOVA G.K., GRUBB A., DUCHARME A., RHODE L.H., LEE R.T., et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. The Journal of clinical investigation, 1999. 104(9): p. 1191-1197.
5. AXEL M.G., BIRGIT L., STEFFEN K.M., OLAV G., RALF W. Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. World journal of gastroenterology: WJG, 2006. 12(5): p. 731.
6. MANUELA G.N., JEAN-PIERRE B., PATRICK M., DOMINIQUE V., IZABELLA M.M., GAD G.K., et al. Cytokine—chemokine and apoptotic signatures in patients with hepatitis C. Translational Research, 2007. 149(3): p. 126-136.
7. MEHDI M., GHODRAT M., ATOOSA F., FARHAD Z., JAFAR N., HOSSEIN N., et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. 2006, LWW. p. 2537-2545.
8. KE W.M., XIE S.B., LI X.J., ZHANG S.Q., LAI J., YE Y.N., et al. There were no differences in serum HBV DNA level between HBeAg‐positive and HBeAg‐negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume. Journal of Viral Hepatitis, 2011. 18(9): p. 637-645.
9. TAKEUCHI M., FUKUDA Y., NAKANO I., KATANO Y., HAYAKAWA T. Elevation of serum cystatin C concentrations in patients with chronic liver disease. European journal of gastroenterology & hepatology, 2001. 13(8): p. 951-955.
10. CHU S.C., WANG C.P., CHANG Y.H., HSIEH Y.S., YANG S.F., SU J.M., et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clinica chimica acta, 2004. 341(1-2): p. 133-138.
11. LADERO J.M., CÁRDENAS M.C., ORTEGA L., ANDREA G.P., FRANCISCA C., MORALES C., et al. Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? Annals of Hepatology, 2012. 11(5): p. 648- 651.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mucteba Can, Mustafa Ergin, Fatih Kivrakoglu, Selman Gencer, Ilhami Yuksel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
